Neuropeptides
Volume 44, Issue 2 , Pages 69-75 , April 2010

Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases

  • Albert Adam

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada H3C 3J7
    • ,
  • Patrick Leclair

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada H3C 3J7
    • ,
  • Nicolas Montpas

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada H3C 3J7
    • ,
  • Gérémy Abdull Koumbadinga

      Affiliations

    • Centre de recherche en rhumatologie et immunologie, Centre Hospitalier Universitaire de Québec, Québec, QC, Canada G1V 4G2
    • ,
  • Hélène Bachelard

      Affiliations

    • Lipid Research Unit, Centre Hospitalier Universitaire de Québec, Québec, QC, Canada G1V 4G2
    • ,
  • François Marceau

      Affiliations

    • Centre de recherche en rhumatologie et immunologie, Centre Hospitalier Universitaire de Québec, Québec, QC, Canada G1V 4G2
    • Corresponding Author InformationCorresponding author. Address: Centre Hospitalier Universitaire de Québec, Centre de Recherche en Rhumatologie et Immunologie, CHUQ, Pavillon CHUL, T1-49, 2705 Laurier Blvd., Québec, QC, Canada G1V 4G2. Tel.: +1 418 656 4141x46155; fax: +1 418 654 2765.

References 

  1. Blais C, Drapeau G, Raymond P, Lamontagne D, Gervais N, Venneman I, et al. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am. J. Physiol. Heart Circ. Physiol. 1997;273:H2263–H2271
  2. Bray GA. The Zucker fatty rat: a review. Fed. Proc. 1977;36:148–153
  3. Brunning P, Holmquist B, Riordan JF. Substrate specificity and kinetic characteristics of angiotensin converting enzyme. Biochemistry. 1983;22:103–110
  4. Carvalho CRO, Thirone APC, Gontijo JAR, Velloso LA, Saad MJA. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes. 1997;46:1950–1957
  5. Costerousse O, Allegrini J, Huang H, Bounhiko J, Alhenc-Gelas F. Regulation of ACE gene expression and plasma levels during rat postnatal development. Am. J. Physiol. Endocrinol. Metab. 1994;267:E745–E753
  6. Décarie A, Drapeau G, Closset J, Couture R, Adam A. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides. 1994;15:511–518
  7. Drimal J, Knezl V, Navarova J, Nedelcevova J, Paulovicova E, Sotnikova R, et al. Role of inflammatory cytokines and chemoattractants in the rat model of streptozotocin-induced diabetic heart failure. Endocr. Regul. 2008;42:129–135
  8. Dumoulin MJ, Adam A, Blais C, Lamontagne D. Metabolism of bradykinin by the rat coronary bed. Cardiovasc. Res. 1998;38:229–236
  9. Erdös EG, Skidgel RA. Metabolism of bradykinin by peptidases in health and disease. In:  Farmer SG editors. The Kinin System. San Diego, CA: Academic Press; 1997;p. 111–141
  10. Gazis A, Page SR, Cockcroft JR. ACE inhibitors, diabetes and cardiovascular disease. Diabetologia. 1998;41:595–597
  11. Henriksen EJ, Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism. 1995;44:267–272
  12. HOPE investigators, 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145–153.
  13. Lamarre NS, Ruggieri MR, Braveman AS, Gerstein MI, Mydlo JH. Effect of obese and lean Zucker rat sera on human and rat prostate cancer cells: implications in obesity-related prostate tumor biology. Urology. 2007;69:191–195
  14. Le Moual H, Devault A, Roques BP, Crine P, Boileau G. Identification of glutamic acid 646 as a zinc-coordinating residue in endopeptidase 24.11. J. Biol. Chem. 1991;266:15670–15674
  15. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 2005;57:27–77
  16. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 1995;47:25–49
  17. Liu RH, Mizuta M, Kurose T, Matsukura S. Early events involved in the development of insulin resistance in Zucker fatty rats. Int. J. Obesity. 2002;26:318–326
  18. Mackay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL, et al. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis. 1992;12:168–184
  19. Moore JW, Pearson RG. Complex reactions. In:  Moore JW,  Pearson RG editor. Kinetics and Mechanism. third ed.. New York: Wiley; 1981;p. 284–296
  20. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, Way KJ, et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes. 2006;55:691–698
  21. Papapetropoulos A, Antonov A, Virmani R, Kolodgie FD, Munn DH, Marczin N, et al. Monocyte- and cytokine-induced downregulation of angiotensin-converting enzyme in cultured human and porcine endothelial cells. Circ. Res. 1996;79:512–523
  22. Prechel MM, Orawski AT, Maggiora LL, Simmons WH. Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J. Pharmacol. Exp. Ther. 1995;275:1136–1142
  23. Ramchandran R, Kasturi S, Douglas JG, Sen I. Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells. Am. J. Physiol. Heart Circ. Physiol. 1996;271:H744–H751
  24. Raut R, Rouleau JL, Blais C, Gosselin H, Molinaro G, Sirois GM, et al. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am. J. Physiol. Heart Circ. Physiol. 1999;276:H1769–H1779
  25. Ryan JW, Berryer P, Chung AYK, Sheffy DH. Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin. J. Pharmacol. Exp. Ther. 1994;269:941–947
  26. Saijonmaa O, Nyman T, Fyhrquist F. Downregulation of angiotensin-converting enzyme by tumor necrosis factor-α and interleukin-1β in cultured human endothelial cells. J. Vasc. Res. 2001;38:370–378
  27. Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am. J. Physiol. Heart Circ. Physiol. 2001;280:H885–H891
  28. Schernthaner G, Schwarzer C, Kuzmits R, Müller MM, Klemen U, Freyler H. Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease. J. Clin. Pathol. 1984;37:307–312
  29. Tatti P, Pahor M, Byington PR, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597–603
  30. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am. J. Hypertens. 1998;11:363–372
  31. Tschöpe C, Gavriluk V, Reinecke A, Seidl U, Riester U, Hilgenfeldt U, et al. Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology. 1996;33:344–348
  32. Uehara M, Kishikawa H, Isami S, Kisanuki K, Ohkubo Y, Miyamura N, et al. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia. 1994;37:300–307
  33. van Dijk DJ, Boner G, Giler S, Erman A. Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat. J. Renin Angiot. Aldo. Syst. 2001;2:193–198
  34. Villard E, Alonso A, Agrapart M, Challah M, Soubrier F. Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells. J. Biol. Chem. 1998;273:25191–25197
  35. Wallenstein S, Zucker CL, Fleis JL. Some statistical methods useful in circulation research. Circ. Res. 1990;47:1–9
  36. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. USA. 1994;91:7742–7746
  37. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?. Hypertension. 2004;43:1120–1125

PII: S0143-4179(09)00108-5

doi: 10.1016/j.npep.2009.09.004

Neuropeptides
Volume 44, Issue 2 , Pages 69-75 , April 2010

Article Tools

* Image Usage & Resolution